



Meet Corey

AGE

32

LOCATION

CALIFORNIA

DIAGNOSED WITH MODERATE-TO-SEVERE
PLAQUE PSORIASIS

2010

STARTED ILUMYA® (TILDRAKIZUMAB) 100 MG/ML

OCTOBER 2019

Psoriasis Journey

Corey's moderate-to-severe plaque psoriasis first came to his attention in 2010 when his sister was cutting his hair and she noticed red, flakey plaques on his hairline. By 2013, his plaques became more widespread and began to develop on other parts of his body – most prominently on his chin, face, knees and back.

He was shocked when his plaques continued to spread. Corey had never heard of moderate-to-severe plaque psoriasis at the time his dermatologist diagnosed him with it.

Because of his moderate-to-severe plaque psoriasis symptoms, Corey would wear long sleeves at work to keep his coworkers from asking about his plaques. Although he knew the questions weren't malicious, they still took a toll on him.

When his symptoms were at their worst, he could not sit down without leaving flakes behind.

Following his diagnosis, Corey's dermatologist prescribed other treatments that did not suppress his moderate-to-severe plaque psoriasis symptoms.

“Socializing became extremely difficult for me because my plaques made me feel gross.”

Finding ILUMYA®

Having experienced moderate-to-severe plaque psoriasis symptoms for the majority of his adult life, Corey was most interested in finding a treatment that would produce long-lasting results

“Prior to ILUMYA®, I felt like I was fighting a losing battle with my moderate-to-severe plaque psoriasis. Now I have an upper hand on it.”

Corey's dermatologist first introduced him to ILUMYA® when they determined that the next treatment step for him was trying a biologic. Corey was excited at this prospect because IL-23 inhibitors were a newer type of treatment for him.

Following his initial doses, Corey noticed that his plaques and flaking were clearing, which he was thrilled about.

ILUMYA® (tildrakizumab-asmn) is a prescription medicine used to treat adults with moderate-to-severe plaque psoriasis who may benefit from taking injections, pills (systemic therapy), or phototherapy. The most common ($\geq 1\%$) adverse reactions for ILUMYA® compared to placebo are upper respiratory infections (14% vs 12%), injection site reactions (3% vs 2%), and diarrhea (2% vs 1%). These are not all of the possible side effects of ILUMYA®. Call your doctor for medical advice.

Road to Lasting Skin Clearance

Now that he is free from plaques, Corey doesn't worry about the state of his skin and feels more comfortable socializing with friends.

For the first time since his late teenage years, he wears short-sleeved shirts and shorts again when the weather is warm. He continues to find lasting skin clearance on ILUMYA® since receiving his initial doses nearly two years ago.

He looks forward to finding continued success on ILUMYA®. In clinical trials, nine out of ten people who achieved clear or almost clear skin after one year were still seeing results five years later.

People living with moderate-to-severe psoriasis should talk to their doctor to determine what treatment option may be right for them. For more information about ILUMYA®, and a downloadable doctor discussion guide, visit [ILUMYA.com/talk-with-your-dermatologist](https://www.sunpharma.com/illumya/talk-with-your-dermatologist).

Learn more about the moderate-to-severe plaque psoriasis journeys of patients like Corey [here](#).

ILUMYA® IS IN IT FOR THE LONG HAUL WITH ME



With ILUMYA®, most people with moderate-to-severe plaque psoriasis can achieve clear or almost clear skin in as little as 12 weeks, and 5 years into treatment, it's still going strong.

Here are some reasons to ask your doctor about ILUMYA®:

- LONG-LASTING RESULTS**
9 out of 10 people who achieved clear or almost clear skin after 1 year were still seeing results 5 years later
- WORKS FROM THE INSIDE**
ILUMYA® works with the body to balance an overactive immune system, addressing symptoms at the source

- DOSING AROUND YOUR SCHEDULE**
4 doses a year after 2 starter doses
- AFFORDABLE TREATMENT**
Eligible patients may pay just \$5 per dose of ILUMYA®*

* \$16,000 maximum program benefit per calendar year. Not valid for patients without commercial insurance coverage or if prescription is paid for by any state or federally funded healthcare program, including but not limited to Medicare, Medicaid, VA, DOD, or TRICARE.

What is ILUMYA?

ILUMYA® (tildrakizumab-asmn) is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections, pills (systemic therapy), or phototherapy (treatment using ultraviolet or UV light).

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about ILUMYA?

Do not use ILUMYA if you have had a severe allergic reaction to ILUMYA or any of its ingredients.

Get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:

- feel faint
- trouble breathing or throat tightness
- swelling of your face, eyelids, lips, mouth, tongue or throat
- chest tightness
- skin rash

ILUMYA is a medicine that may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with ILUMYA and may treat you for TB before you begin treatment with ILUMYA if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with ILUMYA.

Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:

- fever, sweats, or chills
- muscle aches
- weight loss
- cough
- warm, red, or painful skin or sores on your body different from your psoriasis
- diarrhea or stomach pain
- shortness of breath
- burning when you urinate or urinating more often than normal
- blood in your phlegm (mucus)

Before receiving ILUMYA, tell your healthcare provider about all of your medical conditions, including if you:

- have any of the conditions or symptoms listed in the section “What is the most important information I should know about ILUMYA?”
- have an infection that does not go away or that keeps coming back
- have TB or have been in close contact with someone with TB
- recently received or are scheduled to receive a vaccine (immunization). You should avoid receiving live vaccines during treatment with ILUMYA.
- are pregnant or plan to become pregnant. It is not known if ILUMYA can harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if ILUMYA passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

It is not known if ILUMYA is safe and effective in children under 18 years of age.

What are the possible side effects of ILUMYA?

ILUMYA may cause serious side effects. See “What is the most important information I should know about ILUMYA?”

The most common side effects of ILUMYA include upper respiratory infections, injection site reactions and diarrhea. These are not all of the possible side effects of ILUMYA. Call your doctor for medical advice about side effects.

You are encouraged to report any negative side effects of ILUMYA to FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You are also encouraged to report side effects or ADEs (adverse drug events) to our Drug Safety Department at 1-800-406-7984 or drug.safetyUSA@sunpharma.com (preferred) with as much information as available.

Please read the full [Prescribing Information](#) and [Medication Guide](#) for ILUMYA and discuss any questions with your doctor.